Ming-Kuei Jang

CEO
APN LifeSciences

​​​​

Dr. Ming-Kuei Jang, Ph.D., is an internationally recognized expert in neuroscience and molecular imaging, with over two decades of experience in neurodegenerative disease research, molecular diagnostics, and drug development. He is the Founder and Chairman of APRINOIA Therapeutics and is currently spearheading a new initiative focused on building an advanced diagnostic platform for brain health management, with a particular focus on Alzheimer’s and Parkinson’s disease.
This initiative centers on the development of novel PET imaging diagnostics and complementary analytical tools. By integrating conventional and wearable PET scanners with AI-enabled image processing and pattern recognition, Dr. Jang’s team aims to visualize brain pathology to enable early detection, accurate staging, and differential diagnosis. The goal is to deliver a clinically practical and widely accessible solution for managing neurodegeneration, ultimately enabling these diseases to be visible, trackable, and actionable through timely and personalized interventions.
Dr. Jang earned his chemistry degree from National Taiwan University before obtaining a PhD in Pharmacology and Neuroscience from Boston University School of Medicine. He then completed postdoctoral training at Northwestern University and Columbia University. His career includes senior research roles at Merck & Co. and GlaxoSmithKline, where he led biomarker discovery and neuroimaging initiatives. Before founding APRINOIA, he was Director of the Neurodegeneration Consortium at MD Anderson Cancer Center, overseeing translational collaborations with MIT and Baylor College of Medicine.

- Session 1: Development of Next Generation Diagnostic Technologies for Alzheimer’s Disease
- Session 2: Development of Next Generation Treatments for Alzheimer’s Disease
- Removing Brain Pathologies with Immunotherapy and Protein Degraders

.